FY2026 Earnings Estimate for TENX Issued By Leerink Partnrs

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Investment analysts at Leerink Partnrs cut their FY2026 earnings per share (EPS) estimates for Tenax Therapeutics in a research note issued on Tuesday, February 4th. Leerink Partnrs analyst D. Risinger now expects that the specialty pharmaceutical company will post earnings of ($3.93) per share for the year, down from their previous forecast of ($3.91). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ FY2027 earnings at ($4.17) EPS and FY2028 earnings at ($2.70) EPS.

Several other research analysts have also commented on TENX. Guggenheim started coverage on Tenax Therapeutics in a research report on Monday, October 14th. They set a “buy” rating and a $16.00 price target on the stock. Leerink Partners started coverage on Tenax Therapeutics in a research report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Stock Performance

TENX stock opened at $7.23 on Thursday. The business has a 50 day moving average price of $6.15 and a 200 day moving average price of $4.77. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $7.33.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Sphera Funds Management LTD. acquired a new position in Tenax Therapeutics during the third quarter worth $101,000. Stonepine Capital Management LLC acquired a new position in Tenax Therapeutics during the third quarter worth $173,000. Finally, Vestal Point Capital LP acquired a new position in Tenax Therapeutics during the third quarter worth $288,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.